Cargando…

Living with hypertrophic cardiomyopathy and an implantable defibrillator

BACKGROUND: ICDs efficiently terminate life-threatening arrhythmias, but complications occur during long-term follow-up. Patients’ own perspective is largely unknown. The aim of the study was to describe experiences of hypertrophic cardiomyopathy (HCM) patients with implantable defibrillators (ICDs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magnusson, Peter, Jonsson, Jessica, Mörner, Stellan, Fredriksson, Lennart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424404/ https://www.ncbi.nlm.nih.gov/pubmed/28490380 http://dx.doi.org/10.1186/s12872-017-0553-y

Ejemplares similares

Health-related quality of life in hypertrophic cardiomyopathy patients with implantable defibrillators
por: Magnusson, Peter, et al.
Publicado: (2016)

Current Knowledge of Hypertrophic Cardiomyopathy Among Health Care Providers in Sweden
por: Magnusson, Peter, et al.
Publicado: (2020)

Misclassification of hypertrophic cardiomyopathy: validation of diagnostic codes
por: Magnusson, Peter, et al.
Publicado: (2017)

EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM): A prospective observational study on incidence of arrhythmias
por: Magnusson, Peter, et al.
Publicado: (2020)

EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic Cardiomyopathy (ELUCIDATE HCM)—rationale and design: a prospective observational study on incidence of arrhythmias in Sweden
por: Magnusson, Peter, et al.
Publicado: (2017)

Hyaluronan and Collagen in Human Hypertrophic Cardiomyopathy: A Morphological Analysis
por: Hellström, Martin, et al.
Publicado: (2012)

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Positron emission tomography ((15)O-water, (11)C-acetate, (11)C-HED) risk markers and nonsustained ventricular tachycardia in hypertrophic cardiomyopathy
por: Magnusson, Peter, et al.
Publicado: (2019)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

Alcohol Septal Ablation versus Septal Myectomy Treatment of Obstructive Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis
por: Bytyçi, Ibadete, et al.
Publicado: (2020)

Low Molecular Mass Myocardial Hyaluronan in Human Hypertrophic Cardiomyopathy
por: Lorén, Christina E., et al.
Publicado: (2019)

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience
por: Weinstock, Jonathan, et al.
Publicado: (2016)

Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator
por: Francia, Pietro, et al.
Publicado: (2023)

Utilization and Outcomes of Primary Prevention Implantable Cardioverter‐Defibrillators in Patients With Hypertrophic Cardiomyopathy
por: Goldstein, Sarah A., et al.
Publicado: (2023)

Anesthesia in a Child with Newly Diagnosed Hypertrophic Cardiomyopathy for Placement of Implantable Cardioverter Defibrillator
por: Kumar, Rajnish, et al.
Publicado: (2018)

Implantation of cardiac defibrillator in an infant with hypertrophic cardiomyopathy and newly identified MYBP3 mutation
por: Güvenç, Osman, et al.
Publicado: (2020)

Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention
por: Yazaki, Kyoichiro, et al.
Publicado: (2021)

Updated risk assessments for sudden cardiac death in hypertrophic cardiomyopathy patients with implantable cardioverter-defibrillator
por: Park, Yae Min
Publicado: (2023)

Implantable cardioverter-defibrillator implantation should be considered in high-risk patients with apical hypertrophic cardiomyopathy as the same manner with the septal type
por: Park, Y M, et al.
Publicado: (2023)

Long-Term Survival Following Cardiac Arrest Without Implantable Defibrillator Protection in a Hypertrophic Cardiomyopathy Patient
por: Cetin, Mustafa, et al.
Publicado: (2011)

High-Risk Apical Hypertrophic Cardiomyopathy Requiring an Implantable Cardioverter-Defibrillator: A Case Report of an Overlooked Etiology
por: Rathore, Azeem, et al.
Publicado: (2023)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: A paradigm for longitudinal device follow-up
por: Siontis, Konstantinos C., et al.
Publicado: (2021)

Health status measured by Kansas City Cardiomyopathy Questionnaire-12 in primary prevention implantable cardioverter defibrillator patients with heart failure
por: Mattsson, Gustav, et al.
Publicado: (2021)

Atrial fibrillation deteriorates tricuspid regurgitation following implantable cardioverter defibrillator lead placement in patient with hypertrophic obstructive cardiomyopathy
por: Mohri, Takato, et al.
Publicado: (2017)

Obstetric hemorrhage in a case of hypertrophic obstructive cardiomyopathy with automatic implantable cardioverter defibrillator: Anaesthesia and intensive care management
por: Mishra, Sandeep Kumar, et al.
Publicado: (2016)

Progressive electrical remodeling in apical hypertrophic cardiomyopathy leading to implantable cardioverter-defibrillator sensing failure during ventricular fibrillation
por: Fleeman, Blake E., et al.
Publicado: (2016)

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
por: Higgins, Angela Y., et al.
Publicado: (2020)

Performance of the PRIMaCY sudden death risk prediction model for childhood hypertrophic cardiomyopathy: implications for implantable cardioverter-defibrillator decision-making
por: Norrish, Gabrielle, et al.
Publicado: (2023)

A Pregnancy with Severe Hypertrophic Obstructive Cardiomyopathy after Surgery for an Implantable Cardioverter Defibrillator: A Case Report and Literature Review
por: Mitsui, Takashi, et al.
Publicado: (2016)

Inappropriate shock from delayed T-wave oversensing by a subcutaneous implantable cardioverter-defibrillator after septal myectomy for hypertrophic cardiomyopathy
por: Salgado, Benjamin C., et al.
Publicado: (2018)

Takotsubo Cardiomyopathy in the Setting of Hypertrophic Cardiomyopathy Following Pacemaker Implantation
por: Boghdadi, George, et al.
Publicado: (2023)

Genetic screening in sudden cardiac death in the young can save future lives
por: Stattin, Eva-Lena, et al.
Publicado: (2015)

Predictors of Implantable Cardioverter-Defibrillator Use in Patients with Ischemic Cardiomyopathy
por: Kelly, Ryan, et al.
Publicado: (2010)

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2022)

Genetic variants in cardiac calcification in Northern Sweden
por: Hellman, Urban, et al.
Publicado: (2019)

Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?
por: de Groot, Joris R.
Publicado: (2023)

Embodying a New Meaning of Being At Risk: Living With an Implantable Cardioverter Defibrillator for Arrhythmogenic Right Ventricular Cardiomyopathy
por: Manuel, April, et al.
Publicado: (2016)

Balloon venoplasty opens the road for an implantable defibrillator patient with complex stenosis
por: Magnusson, Peter, et al.
Publicado: (2017)

Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging – a case report
por: Kurath-Koller, Stefan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_geeekbnn9hp76g8i7b3nf7qe02